Following the press release issued by Biogen regarding their plans on regulatory filing for Aducanumab in Alzheimer’s disease based on new analysis of larger dataset from Phase 3 studies, we are pleased to announce that these results will be presented at CTAD 2019 on Thursday, December 5 at 8am.

https://www.ctad-alzheimer.com/